🔍

MEDPLUS - Medplus Health

📊 NSE: MEDPLUS 🏢 Trading 📅 Last Updated: 12/14/2025 9:46

📢 Recent Corporate Announcements

MedPlus Subsidiary Store in Odisha Faces 3-Day License Suspension; Revenue Impact ₹1.38 Lakhs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 10 Mar 2026, 05:48 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a store in Baragarh, Odisha. The suspension is for a period of three days following an order from the Deputy Drugs Controller, Sambalpur. The action was taken due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates the total financial impact of this suspension to be a revenue loss of approximately ₹1.38 lakhs.

Drug license of a store in Baragarh, Odisha, suspended for a duration of 3 days
Action initiated by the Deputy Drugs Controller, Western Zone, Sambalpur
Alleged violation of Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹1.38 lakhs
Order received by subsidiary Optival Health Solutions on March 9, 2026

💡 No immediate action is required as the financial impact is immaterial to the company's overall operations. Investors should view this as a minor localized regulatory issue.

MedPlus Subsidiary Faces 7-Day Drug License Suspension for Pune Store; ₹3.85 Lakh Revenue Impact

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 04 Mar 2026, 12:34 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received a suspension order for the drug license of its store located in Sangvi, Pune. The suspension, issued by the FDA Maharashtra, is effective for seven days due to violations of Rule 65 of the Drugs and Cosmetics Act. The company has quantified the potential revenue loss at approximately ₹3.85 lakhs. While the financial impact is negligible on a consolidated basis, it reflects localized regulatory enforcement actions.

Drug license for the Sangvi, Pune store suspended for a period of 7 days
Estimated potential revenue loss during the suspension period is ₹3.85 lakhs
Action taken by the Assistant Commissioner & Licensing Authority, FDA Pune, Maharashtra
Suspension based on alleged violations of Rule 65 of the Drugs and Cosmetics Rules, 1945

💡 This is a minor regulatory event with no material impact on the company's overall valuation. Investors should monitor if such compliance issues become frequent across multiple locations.

MedPlus Subsidiary Receives One-Day Drug License Suspension for Telangana Store

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 28 Feb 2026, 06:23 PM

MedPlus Health Services Limited has informed that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Kuntloor, Telangana. The suspension, issued by the Drugs Control Administration of Rangareddy, is for a duration of only one day. The action was taken due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a negligible financial impact with a potential revenue loss of approximately Rs 0.42 lacs.

One-day suspension of drug license for a store located in Kuntloor, Telangana
Action initiated by the Assistant Director, Drugs Control Administration, Rangareddy
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss is minimal at Rs 0.42 lacs

💡 No action is required as the financial impact is immaterial to the company's consolidated operations. This is a minor regulatory compliance matter at a single retail outlet.

Medplus Health Services to Attend Nirmal Bang Investor Conference on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 05:31 PM

Medplus Health Services Limited has scheduled a virtual meeting with analysts and institutional investors for March 6, 2026, at 2:00 PM. The company will be participating in the Nirmal Bang Sector Specific Conference, represented by its Key Managerial Personnel. This interaction is a standard regulatory disclosure under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the session.

Virtual meeting scheduled with Nirmal Bang Sector Specific Conference on March 6, 2026.
The session is set to commence at 02:00 PM IST.
Key Managerial Personnel (KMP) will represent the company during the interaction.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 No immediate action is required as this is a routine investor interaction. Investors may look for post-meeting transcripts or presentations on the company website for insights into management's outlook.

MedPlus Subsidiary Faces 7-Day License Suspension for Guntur Store; Revenue Impact ₹2.22 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 26 Feb 2026, 05:37 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for its drug license at a store in Guntur, Andhra Pradesh. The suspension is effective for seven days following violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately ₹2.22 lacs during this period. While the financial impact is negligible compared to the company's total revenue, it reflects ongoing regulatory compliance monitoring in the retail pharmacy sector.

Drug license for the SVN Colony Guntur store suspended for a period of 7 days
Order issued by the Drugs Control Administration, Guntur, Andhra Pradesh on February 25, 2026
Suspension due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹2.22 lacs
Action taken against subsidiary Optival Health Solutions Private Limited

💡 This is a minor regulatory event with insignificant financial impact on the company's overall operations. Investors should treat this as a routine compliance matter and no immediate portfolio action is necessary.

MedPlus Seeks Shareholder Nod for ₹11,262.20 Mn Related Party Transaction with Subsidiary

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 24 Feb 2026, 09:39 PM

MedPlus Health Services has initiated a postal ballot to seek shareholder approval for material related party transactions (RPT) with its subsidiary, Optival Health Solutions Private Limited. The proposed transactions for the financial year 2026-27 are capped at an aggregate value of ₹11,262.20 million. This approval is mandatory under SEBI regulations as the transaction value exceeds 10% of the company's annual consolidated turnover. The e-voting period for shareholders is scheduled from February 25 to March 26, 2026.

Proposed RPT with material subsidiary Optival Health Solutions for FY 2026-27.
Aggregate transaction limit set at ₹11,262.20 million plus applicable taxes.
Transactions exceed the 10% materiality threshold of annual consolidated turnover.
Remote e-voting period runs from February 25, 2026, to March 26, 2026.
Board confirms transactions are in the ordinary course of business and at arm’s length.

💡 Investors should note this as a standard regulatory compliance procedure for large-scale inter-company operations; no immediate portfolio changes are recommended.

Medplus Subsidiary Store in Telangana Faces 3-Day License Suspension

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 23 Feb 2026, 05:38 PM

Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for its drug license at a single store in Telangana. The suspension, issued by the Drugs Control Administration, is for a duration of three days starting from the receipt of the order on February 22, 2026. The company cited a violation under Rule 65 of the Drugs and Cosmetics Act, 1940. The financial impact is negligible, with an estimated revenue loss of approximately ₹0.76 lacs.

Drug license for one store in Surya Nagar Colony Mallpur, Telangana, suspended for 3 days
Action taken by the Assistant Director, Drugs Control Administration, Shameerpet
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss is minimal at ₹0.76 lacs

💡 No action is required as the financial impact is immaterial to the company's overall operations. This appears to be a routine localized regulatory matter.

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka; Revenue Loss of ₹4.19 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 21 Feb 2026, 05:20 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received suspension orders for drug licenses at two stores in Davanagere, Karnataka. The first store at Vinobha Nagar faces a 5-day suspension with a projected revenue loss of ₹1.40 lacs. The second store at KSRTC Davanagere faces a 7-day suspension with a projected revenue loss of ₹2.79 lacs. These actions were taken due to violations of Rule 65 of the Drugs and Cosmetics Act, 1940. While the financial impact is negligible relative to the company's total scale, it indicates localized regulatory oversight.

Suspension of drug licenses for two stores in Davanagere, Karnataka, due to Rule 65 violations.
Store at Vinobha Nagar suspended for 5 days with a potential revenue loss of ₹1.40 lacs.
Store at KSRTC Davanagere suspended for 7 days with a potential revenue loss of ₹2.79 lacs.
Total quantifiable financial impact estimated at a minor ₹4.19 lacs.
Orders were issued by the Assistant Director, Drugs Control Administration, Davanagere Circle.

💡 No immediate action is required as the financial impact is immaterial to the company's overall operations. Investors should monitor if such regulatory suspensions become a recurring pattern across more locations.

MedPlus Subsidiary Receives One-Day License Suspension for Karnataka Store; Revenue Impact ₹0.33 Lacs

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 20 Feb 2026, 04:51 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions, has been ordered to suspend operations at one store in Tumkur, Karnataka, for a single day. The order, received on February 19, 2026, stems from violations of Rule 65 of the Drugs and Cosmetics Act. The company estimates a minimal revenue loss of approximately ₹0.33 lacs from this suspension. Such localized regulatory actions are common in the retail pharmacy sector and have no material impact on consolidated financials.

Drug license suspended for one day at the Koratagere store in Tumkur, Karnataka.
Action taken by the Drugs Control Administration under Rule 65 of the Drugs and Cosmetics Act.
Quantifiable financial impact is a negligible revenue loss of ₹0.33 lacs.
The order was officially received by the subsidiary on February 19, 2026.

💡 This is a minor operational event with no impact on the company's valuation. Investors can treat this as a routine regulatory compliance matter with no material consequence.

MedPlus Subsidiary Faces 7-Day Drug License Suspension for Andhra Pradesh Store

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Feb 2026, 06:43 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for the drug license of its store in Eluru, Andhra Pradesh. The suspension is for a period of seven days due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately Rs 4.28 lacs during this period. While the financial impact is minimal, it highlights regulatory oversight on pharmacy operations.

Drug license suspended for 7 days at the Eluru store in West Godavari District, Andhra Pradesh
Action initiated by the Drugs Control Administration under Rule 65 of Drugs and Cosmetics Rules
Estimated potential revenue loss quantified at Rs 4.28 lacs
Order received on February 12, 2026, affecting subsidiary Optival Health Solutions Private Limited

💡 No immediate action is required as the financial impact is negligible compared to the company's total revenue. Investors should treat this as a routine regulatory update but monitor for any pattern of recurring compliance issues.

MedPlus Subsidiary Faces 15-Day Drug License Suspension for Pune Store; ₹6.27 Lakh Revenue Impact

🔴 NEGATIVE ⭐ 3/10

REGULATORY 📅 04 Feb 2026, 05:57 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for the drug license of its store located in Sasanenagar, Pune. The suspension is effective for 15 days following an order from the Food & Drug Administration, Maharashtra, due to violations under Rule 65 of the Drugs and Cosmetics Act. The company estimates a potential revenue loss of approximately ₹6.27 lakhs during this period. While the financial impact is minor, it highlights ongoing regulatory oversight in the pharmacy retail sector.

15-day drug license suspension for a specific store in Sasanenagar, Pune, Maharashtra
Estimated potential revenue loss of ₹6.27 lakhs due to the temporary closure
Action taken by the Assistant Commissioner & Licensing Authority, FDA, Maharashtra
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945
Order received on February 3, 2026, and disclosed on February 4, 2026

💡 The financial impact is immaterial to the company's consolidated financials; however, investors should monitor for any patterns of regulatory non-compliance across other store locations.

MedPlus Q3 FY26: Strong 10%+ SSSG and 182 Net Store Additions Drive Growth

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 03:22 PM

MedPlus Health Services reported a robust Q3 FY26 with consolidated revenue of ₹1,806.1 crore and an operating EBITDA of ₹96.8 crore (5.4% margin). A key highlight was the recovery in Same Store Sales Growth (SSSG) to over 10%, attributed to revised store-level incentive structures and better product availability. The company added 182 net stores during the quarter, bringing the total network to 5,112, and remains on track for its 600-store annual target. The diagnostics segment also showed healthy growth with revenue reaching ₹32.67 crore and margins improving to 15.5%.

Achieved 10%+ Same Store Sales Growth (SSSG) following strategic tweaks to store incentive structures.
Net addition of 182 stores in Q3, reaching a total network of 5,112 stores across 2.6 million sq. ft.
Private label pharma GMV share reached 18.9%, a significant jump from 7.9% in the prior year's first quarter.
Diagnostics segment revenue grew to ₹326.7 million with an improved operating EBITDA margin of 15.5%.
Consolidated EBITDA of ₹96.8 crore includes a non-recurring charge of ₹7.06 crore for new Labour Code implementation.

💡 Investors should view the return to double-digit SSSG and the scaling of the high-margin diagnostics business as positive indicators of operational efficiency. Monitor the upcoming full-scale rollout of the franchisee model as a potential catalyst for capital-light expansion in FY27.

MedPlus Health Submits Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 11:18 PM

MedPlus Health Services Limited has officially submitted the audio recording of its earnings call held on February 02, 2026, at 16:00 IST. The call focused on the company's financial performance for the third quarter ended December 31, 2025 (Q3 FY26). This is a routine regulatory filing under SEBI (LODR) Regulations to ensure transparency for all stakeholders. Investors can access the recording via the company's website or stock exchange portals to hear management's detailed commentary.

Audio recording of the Q3 FY26 earnings call released on February 02, 2026.
The call discussed financial results for the quarter ended December 31, 2025.
Submission made in compliance with SEBI Regulation 30(6) and Schedule III.
Recording is accessible via a direct link on the company's official website.

💡 Investors should listen to the recording to understand management's outlook on store expansion and margin trends for the upcoming quarters.

MedPlus Subsidiary Faces 25-Day Drug License Suspension for Maharashtra Store

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 31 Jan 2026, 06:40 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has been ordered to suspend operations at its Bhandara, Maharashtra store for 25 days. The suspension follows a violation of Rule 65 of the Drugs and Cosmetics Act, 1940, as determined by the state FDA. The company has quantified the potential revenue loss from this suspension at approximately ₹7.53 lacs. While the financial impact is negligible on a consolidated basis, it reflects ongoing regulatory oversight in the retail pharmacy segment.

Drug license for the Bhandara store suspended for a duration of 25 days
Estimated potential revenue loss of ₹7.53 lacs during the suspension period
Action taken by the Assistant Commissioner & Licensing Authority, FDA, Maharashtra
Violation pertains to Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945

💡 No immediate action is required as the financial impact is insignificant compared to the company's total revenue. Investors should monitor for any patterns of recurring regulatory non-compliance across other store locations.

MedPlus Subsidiary Faces One-Day Drug License Suspension for Telangana Store

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 30 Jan 2026, 05:10 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Telangana. The suspension, issued by the Drugs Control Administration, Patancheru, is for a duration of one day. The order was issued under Rule 66(1) of the Drugs and Cosmetics Act, 1940. The company estimates a negligible financial impact with a potential revenue loss of only Rs 0.20 lacs.

One-day suspension of drug license for a store located in Kardanur, Telangana
Action initiated by the Assistant Director, Drugs Control Administration, Patancheru
Violation cited under Rule 66(1) of the Drugs and Cosmetics Rules, 1945
Estimated revenue loss is approximately Rs 20,000 (Rs 0.20 lacs)

💡 This is a routine regulatory disclosure with immaterial financial impact; no specific action is required from investors.

View All MEDPLUS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 9.17% in FY 2025 to INR 61,846.69 million. By segment: Retail grew 8.6% to INR 60,268.86 million; Diagnostic services grew 44.3% to INR 1,081.07 million; and Other segments grew 15.4% to INR 10.60 million.

Geographic Revenue Split

The company operates 4,930 stores across 13 states and 1 union territory. In Q2 FY 2026, 68 net store additions were made beyond Tier-One cities, aligning with the strategy to deepen retail healthcare access in underserved markets.

Profitability Margins

Consolidated gross margin increased from 21.92% in FY 2024 to 24.37% in FY 2025, reaching a new high of 26.1% in Q2 FY 2026. This 240 bps YoY improvement is driven by the increasing share of high-margin private label products.

EBITDA Margin

Consolidated operating EBITDA for Q2 FY 2026 stood at 5.3% (INR 887 million). Mature outlets (older than 12 months) maintained a solid 11.8% store-level EBITDA margin, demonstrating strong unit economics upon store maturity.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company added 145 gross stores in Q2 FY 2026 and maintains a property bank of 400+ locations for future expansion.

⚙️ Operational Drivers

Raw Materials

Branded pharmaceutical products represent approximately 75% of sales. Private label pharmaceuticals and FMCG goods constitute 21.5% of total revenue as of Q2 FY 2026.

Capacity Expansion

Current network includes 4,930 stores covering 2.6 million+ square feet as of Q2 FY 2026. The company added 398 stores in FY 2025 and 117 net stores in Q2 FY 2026.

Raw Material Costs

Cost of goods sold was INR 46,406.61 million in FY 2025, representing 75.03% of total income, down from 77.52% in FY 2024 due to better supply chain efficiency.

Manufacturing Efficiency

The company utilizes a backward-integrated value chain and tech-driven inventory management to maintain cost efficiency across 48k+ SKUs in warehouses.

📈 Strategic Growth

Expected Growth Rate

6.50%

Growth Strategy

Growth will be driven by a cluster-based expansion strategy focusing on deeper penetration in 13 states, a pilot franchisee model, and increasing private label revenue share to 20-25%. The company is also expanding its diagnostics segment, which grew 44.3% in FY 2025.

Products & Services

Branded and private-label medicines, wellness products, FMCG goods, pathology and radiology diagnostic services, and insurance broking.

Brand Portfolio

MedPlus, MedPlus Mart, MedPlus Lens, MedPlus Labs.

New Products/Services

Private label pharma sales reached 12.1% of revenue in Q2 FY 2026, while non-pharma private labels contributed 9.6%.

Market Expansion

Expansion into Tier II and III cities to capitalize on rising health awareness and underserved retail healthcare markets.

Market Share & Ranking

2nd largest pharmacy retailer in India by revenue.

🌍 External Factors

Industry Trends

The Indian retail pharmacy industry is growing rapidly and moving toward consolidation and digital transformation. MedPlus is positioned as a pioneer in the organized retail format with a 19-year presence.

Competitive Landscape

Intense competition from both traditional unorganized retail pharmacies and well-funded online pharmacy platforms.

Competitive Moat

Durable advantages include a backward-integrated supply chain, a massive network of 4,900+ stores, and high customer stickiness (70% retention) through loyalty programs. These are sustainable due to the high capital requirement for competitors to build similar infrastructure.

Macro Economic Sensitivity

Sensitive to India's growing chronic disease burden and increasing internet penetration which drives ePharmacy (omnichannel) demand.

Consumer Behavior

Shift toward impulsive buying in the non-pharma/FMCG segment, where there is no doctor-prescribed dosage limit, driving higher basket values.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily influenced by the Drug Pricing Control Order (DPCO) and compliance with various pharmaceutical retail and diagnostic licensing laws.

Legal Contingencies

No material changes, commitments, or insolvency proceedings were initiated during the financial year ended March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

Promoter share pledging is identified as a financial risk that affects investor confidence. Pharmacist attrition is an HR risk that could impact service quality.